Methods: Adult patients were randomized to receive cyclophosphamide alone (50 mg orally once daily) or with veliparib (60 mg orally once daily) in 21-day cycles. Crossover to the combination was allowed at disease progression.
INTRODUCTION
Poly(ADP-ribose) polymerase (PARP) 1 and 2 enzymes regulate DNA damage repair and maintain genomic stability in cells. Inhibition of DNA repair by small molecule PARP inhibitors potentiates DNA damage caused by cytotoxic chemotherapies, including cyclophosphamide (1) (2) (3) . Inhibition of PARP activity in the presence of deleterious mutations in the BRCA gene, which is involved in the homologous recombination pathway of DNA damage repair, can result in tumor cell death through the process of synthetic lethality (4, 5) . Clinical activity is observed with PARP inhibitors alone and in combination with cytotoxic chemotherapy in patients with breast or ovarian cancers carrying germline BRCA mutations (BRCA-mutant) (6) (7) (8) . Clinical responses have also been observed with PARP inhibitors in patients with high-grade serous ovarian cancer (HGSOC), a disease known to have a high incidence of DNA repair defects even in patients who do not carry germline BRCA mutations (9). (10) (11) (12) (13) . Our phase 1 study of oral cyclophosphamide in combination with veliparib was well tolerated and demonstrated activity in patients with BRCA-mutant tumors: 6 of 13 patients experienced a partial response (PR), and 3 additional patients had prolonged disease stabilization (14) . Based on this promising activity, we conducted a multicenter, randomized phase 2 trial to compare the response rate (complete plus partial responses; CR+PR) of veliparib in combination with oral cyclophosphamide to that of oral cyclophosphamide alone in patients with pretreated BRCA-mutant ovarian cancer or in patients with pretreated HGSOC, primary peritoneal, or fallopian tube cancers. This trial was designed to Author Manuscript Published OnlineFirst on January 14, 2015; DOI: 10.1158/1078-0432.CCR- estimate the relative contribution of PARP inhibition to the activity of this combination in patients with known BRCA mutations or in tumors known to have a high incidence of DNA repair defects (9). Secondary objectives were to evaluate archival tissue and blood samples for mutations in genes involved in DNA damage repair and determine poly(ADP-ribose) (PAR) levels in peripheral blood mononuclear cells (PBMCs) and levels of phosphorylated histone H2AX (γH2AX), a marker of DNA damage response, in circulating tumor cells (CTCs) before and during treatment (15, 16) . Archival patient tumor samples were sequenced for 211 genes involved in DNA damage repair thought to possibly affect the therapeutic potential of both cyclophosphamide and PARP inhibitors. We also performed gene expression profiling to examine whether the expression of specific DNA repair genes might correlate with PARP mRNA levels, BRCA mutation status, or response to therapy.
MATERIALS AND METHODS

Eligibility criteria
Patients 18 years of age or older with histologically documented BRCA mutation-positive ovarian cancer (documented deleterious BRCA1/2 mutation or a BRCAPRO score (17) of ≥ 30%) were eligible to participate. Patients with primary peritoneal cancer, fallopian tube cancer, or HGSOC were also eligible to participate, regardless of BRCA mutation status. All patients were required to have received at least one line of standard therapy and have measurable disease.
A Karnofsky performance status ≥ 70% and adequate liver, kidney, and marrow function defined as an absolute neutrophil count ≥ 1,500/μL, platelets ≥ 100,000/μL, total bilirubin ≤ 1.5 X the upper limit of normal (ULN), aspartate aminotransferase and/or alanine aminotransferase < 2.5 X Research. 
Trial design
This was an open-label, multicenter, randomized phase 2 study of the combination of veliparib and oral cyclophosphamide compared to oral cyclophosphamide alone in patients with pretreated primary peritoneal cancer, fallopian tube cancer, HGSOC, or BRCA-mutant ovarian cancer.
Veliparib (ABT-888) was supplied by the Division of Cancer Treatment and Diagnosis, NCI, under a Collaborative Research and Development Agreement with AbbVie (North Chicago, IL).
Cyclophosphamide was obtained from commercial sources.
Oral cyclophosphamide was administered at 50 mg once daily, alone or with oral veliparib at 60 mg once daily throughout a 21-day cycle, the same combination regimen studied in our prior phase 1 trial (14) . Patients were required to maintain a diary documenting when drugs were taken and any associated side effects. There were no restrictions on food consumption. The trial was randomized and used a phase 2.5 design, intending to enroll 65 patients per arm in order to have 80% power to permit a 0.10 alpha level one-sided test to compare clinical responses of 35% for the combination therapy to 15% for single-agent cyclophosphamide (19) .
In addition, there was 80% power to perform a 0.10 alpha level one-sided test to compare 6-month progression free survival (PFS) probabilities between the arms. The study had a provision for an early stopping rule: if approximately 50% of the intended patients (approximately [32] [33] per arm) had responses evaluated and the response rate on the combination arm was less than that of single agent cyclophosphamide, then accrual would end whenever this was determined.
Patient data were analyzed with and without being stratified by known BRCA mutation status.
Correlative Studies
Formalin-fixed paraffin-embedded (FFPE) archived tumor tissue samples were collected and the tumor content was assessed from a Hematoxylin and Eosin (H and E) stained 4 µm section of the specimen. If tumor content was found to be less than 70% of the total cellular content in the section, a manual macro-dissection of the remaining tissue was performed to enrich for tumor cells (Figure 1 ). DNA and RNA were extracted using Qiagen AllPrep DNA/RNA FFPE Kits.
For the whole exome capture sequence analysis, a total of 500 ng fragmented DNA for each Author Manuscript Published OnlineFirst on January 14, 2015; DOI: 10.1158/1078-0432.CCR- sample was used to make a sequencing library by hybridization with Agilent SureSelectXT Human All Exon 50Mb capture baits, followed with sequencing on the Illumina HiSeq 2000 platform. Gene expression profiling was performed on the Affymetrix U133plus2 GeneChip (methods available in the Supplementary Data). Mutation and gene expression data were analyzed to identify any subset of patients benefitting from veliparib treatment using the crossvalidated adaptive signature design approach (20) . The same data were also interrogated with a multivariate penalized Cox proportional hazards model to investigate if any of the genes were associated with the hazard of disease progression in either the cyclophosphamide only or combination cohorts.
Whole blood for PBMC and CTC isolation and analysis was collected from patients enrolled at the NCI only. Specimens for CTC analysis were collected into 7.5 mL CellSave tubes (Veridex) at baseline (prior to administration of study drugs), 24 hours after dosing on cycle 1, day 1, before drug on cycle 2 day 1, and just prior to each restaging (every 3 cycles); levels of γH2AX were determined as previously described (16) . Blood for PBMCs was collected into 8 mL Cell
Prep tubes (Becton Dickinson) on cycle 1 day 1 at baseline and at 4 and 24 hours after drug, on cycle 2 day 1 before dosing and 4 hours after drug, and just prior to each restaging; poly(ADPribose) (PAR), a product of PARP, was measured as previously described (21) . PBMC and CTC sampling were repeated after patient crossover.
RESULTS
Demographics
Research. Seventy-five patients were enrolled (Table 1) ; treatment was discontinued for one patient due to adverse events, one patient withdrew from the study, and one patient died before the end of the first cycle, leaving 72 patients evaluable for response (Table 1) . Of these, 37 received cyclophosphamide alone and 35 the combination as their initial treatment regimen. Patients were heavily pretreated, all having received prior platinum and taxanes with the exception of patient #1071 who did not receive taxanes. Two patients had received prior PARP inhibitor therapy (niraparib, olaparib, veliparib) and three patients had received prior cyclophosphamide. No patient was eligible based on a BRCAPRO score alone.
Toxicity
Grade 2/3 leucopenia and lymphopenia were the most common adverse events experienced by patients receiving cyclophosphamide alone or in combination (Table 2) ; grade 4 lymphopenia and grade 4 thrombocytopenia were reported in two separate patients receiving the combination, necessitating dose reduction. There was a trend towards increased myelosuppression with the combination compared to single agent cyclophosphamide; however, both treatment regimens were well tolerated and the toxicities were easily managed.
Efficacy
The addition of veliparib to cyclophosphamide did not improve the response rate over cyclophosphamide alone, and patient accrual ended early per the stopping rule defined in the protocol. Out of 70 total patients with responses reported, one patient in each arm (#1095 and #1088) had a CR. PR was seen in six patients in the cyclophosphamide-only arm [7/36 (19.4%) Research. 
Correlative Studies
PAR levels were determined in PBMC samples collected before and after co-administration of veliparib from 10 patients on the combination arm and 11 patients who had crossed over to the combination arm. Four hours after treatment, PAR levels were reduced by at least 48% compared to baseline in all samples (mean, 85%; standard deviation, 13%) and were rebounding in most patients by 24 hours post-treatment (Supplemental Figure S2) . Sufficient CTC counts (≥6 CTCs) were isolated in samples from 10 (5 from each treatment arm) of 23 patients analyzed; counts ranged from 6-24 per 7.5 mL whole blood (data not shown). An increase in γH2AX-positive CTCs was observed in the only patient for whom quantitative analysis could be performed (data not shown).
A panel of 211 genes selected for their involvement in DNA repair (Supplemental Table S1) were interrogated by whole exome-capture sequencing and gene expression profiling in tumor tissue from 55 patients (27 treated with cyclophosphamide alone and 28 with the combination).
All 55 patients had deleterious mutations (i.e., nonsynonymous mutations at coding regions) in at least 4 (and up to 70) of the genes evaluated, with an average of 9.3 mutations per patient ( Table   3 ). The most common mutations observed, by far, were in TP53, followed by BRCA1; our patients displayed proportionally higher frequencies of mutations in DNA repair genes such as BRCA1, BRCA2, and APC than are commonly found in ovarian serous carcinoma (Table 4) . We observed no significant difference in either the total number of genes mutated or the mutational frequency of any particular gene between those patients who did or did not respond to treatment.
Gene expression profiling over the 211 DNA repair genes was suggestive of two different
Research. 
populations within the 55 patients, but these populations did not align with BRCA mutational status, patient response, or any other characteristic that we could demonstrate (Supplemental Figure S3 and Supplemental Excel file).
We used the cross-validated adaptive signature design approach (20) to analyze whether the mutation status or expression levels of the genes in our DNA repair panel could be used to identify a subset of patients who benefited from PARP inhibitor treatment. Although 22 genes with a p-value less than 0.05 were identified (Supplemental Table S2 ), none of the genetic alterations were significantly associated with veliparib treatment benefit when adjusted for multiplicity to control for the false discovery rate. The selected variables were therefore not sufficient to build a reliable predictor to select patients who would benefit from PARP inhibitor therapy.
DISCUSSION
The combination of PARP inhibitors with cytotoxic chemotherapy has been poorly tolerated with enhanced myelosuppression limiting the doses of chemotherapy that can be safely administered (22) . The combination of oral cyclophosphamide with veliparib, however, was well tolerated and could be safely administered on a chronic schedule providing uninterrupted PARP inhibition to the majority of patients (14); therefore, we decided to address the question of the relative contribution of PARP inhibition to the clinical activity of the combination by comparing veliparib with oral cyclophosphamide to oral cyclophosphamide alone in ovarian tumors carrying BRCA mutations or in gynecologic cancers known to have a high incidence of DNA repair defects (9). Even though oral cyclophosphamide has demonstrated activity in combination 
average of 85% 4 hours after the first administration of veliparib; however, given the modest response rates observed we could not correlate PAR inhibition to clinical benefit. PARP inhibitors can function both by inhibiting the catalytic activity of PARP, resulting in persistent, unrepaired DNA single strand breaks, and by trapping PARP-DNA complexes, interfering with DNA replication (30) (31) (32) , Although a potent catalytic inhibitor of PARP (33) , in cell lines veliparib causes less PARP trapping than some other PARP inhibitors at catalytically inactivating concentrations (32) . The relative contribution of PARP-DNA trapping to the clinical activity of PARP inhibitors in combination with cytotoxic chemotherapy is not known.
In addition, the role of PARP in modulating the activity of low dose cyclophosphamide is postulated but not proven in the clinic.
Platinum sensitivity appears to be one of the determinants of response to PARP inhibitor therapy (34) (35) (36) . In our trial, all patients had received prior platinum; however, we did not collect consistent data to determine the fraction of patients who had platinum sensitive disease and how that correlated with clinical benefit on either arm. In view of our randomized trial design, we presume but cannot prove that the arms were evenly balanced with regard to the number of patients with platinum-sensitive versus -resistant disease.
We also performed an exploratory analysis of the mutation status and expression levels of 211 selected genes involved in DNA damage response. Widespread defects in pathways such as homologous recombination, non-homologous end joining, mismatch repair, Fanconi anemia, and DNA replication were observed; however, the presence of these DNA repair defects did not predict for response to either cyclophosphamide or the combination of veliparib and Research. 
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